Shanghai Henlius Biotech (HKG:2696) obtained approval for the biologics license application of POHERDY injection for intravenous use from the US Food and Drug Administration (FDA), a Friday Hong Kong bourse filing said.
The approved indications include use in combination with trastuzumab and chemotherapy in the treatment of adults with breast cancer.